Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Adobe Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,983,395

238 payments

Through program year 2025, Adobe Clinical Research LLC is reported as receiving $1,983,395 in research payments, across 238 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,149,724 112
2024 Research $392,633 28
2023 Research $130,583 10
2021 Research $42,883 22
2020 Research $35,858 9
2019 Research $231,712 57

Breakdown

Who paid Research payments · program years 2019–2025
  1. Madrigal Pharmaceuticals $1,124,824 76 payments
  2. Regeneron Pharmaceuticals, Inc. $401,384 57 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $203,758 42 payments
  4. Ironwood Pharmaceuticals, Inc $119,728 20 payments
  5. Shire North American Group Inc $82,472 25 payments
  6. Allergan Inc. $48,905 14 payments
  7. Bausch Health US, LLC $1,500 3 payments
  8. Celgene Corporation $824 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Multinational Doubleblind Randomized Placebocontrolled Study of Mgl3196 Resmetirom in Patients With Nonalcoholic Steatohepatitis Nash and Fibrosis to Resolve Nash and Reduce Progression to Cirrhosis Andor Hepatic Decompensation $607,365 30 payments
  2. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors $401,384 57 payments
  3. A 52Week Phase 3 Openlabel Extension Study With A Doubleblind Leadin to Evaluate Safety and Biomarkers of Resmetirom Mgl3196 in Patients With Nonalcoholic Fatty Liver Disease Nafld Maestronafldopenlabelextension Maestronafldole $319,513 19 payments
  4. A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $197,946 27 payments
  5. A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet $138,733 16 payments
  6. C3718-301 $89,463 15 payments
  7. Oral Budesonide Suspension Obs in Adolescents and Adult Subjects With Eosinophilic Esophagitis DB, Placebo-Controlled, RW $54,838 20 payments
  8. A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders With Moderately to Severely Active Ulcerative Colitis (Enterpret) $36,171 15 payments
  9. McP-103-312 $30,265 5 payments
  10. Oral Budesonide Suspension Obs in Adolescents and Adult Subjects With Eosinophilic Esophagitis DB, Maintenance $27,634 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $17,375 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record